Conversely, downregulation of DLC1 via genetic and epigenetic mechanisms occurs frequently in a variety of cancers, including liver cancer, lung cancer, colorectal cancer, prostate cancer, and breast cancer [26, 39–41]. This evidence concerns the gene DLC1 and Familial prostate cancer.